Arcadia Biosciences (RKDA) Stock Price, News & Analysis

Company Overview

Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas.

Key Stats

• Today's Range: $5.94 to $6.19
• 50-Day Range: $2.65 to $6.40
• 52-Week Range: $1.85 to $10.31
• Volume: 31,439 shs
• Average Volume: 314,469 shs
• Market Capitalization: $8.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Strong Buy

Arcadia Biosciences Stock Analysis - MarketRank™

Arcadia Biosciences scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Arcadia Biosciences has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Arcadia Biosciences has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Arcadia Biosciences are expected to grow in the coming year, from ($1.70) to $0.12 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Arcadia Biosciences is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Arcadia Biosciences is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Arcadia Biosciences has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.54% of the float of Arcadia Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Arcadia Biosciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Arcadia Biosciences has recently increased by 1,175.82%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Arcadia Biosciences does not currently pay a dividend.

Dividend Growth

Arcadia Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.54% of the float of Arcadia Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Arcadia Biosciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Arcadia Biosciences has recently increased by 1,175.82%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.69

News Sentiment

Arcadia Biosciences has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Basic Materials companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Arcadia Biosciences this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for RKDA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Arcadia Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.80% of the stock of Arcadia Biosciences is held by insiders.

Percentage Held by Institutions

Only 17.73% of the stock of Arcadia Biosciences is held by institutions.

RKDA Stock Analysis - Frequently Asked Questions

How have RKDA shares performed this year?

Arcadia Biosciences' stock was trading at $3.13 at the beginning of 2024. Since then, RKDA stock has increased by 93.0% and is now trading at $6.04.
View the best growth stocks for 2024 here.

How were Arcadia Biosciences' earnings last quarter?

Arcadia Biosciences, Inc. (NASDAQ:RKDA) issued its quarterly earnings data on Tuesday, August, 13th. The basic materials company reported $0.78 earnings per share for the quarter, missing the consensus estimate of $1.27 by $0.49. The basic materials company had revenue of $1.31 million for the quarter, compared to the consensus estimate of $0.95 million. Arcadia Biosciences had a negative trailing twelve-month return on equity of 52.63% and a negative net margin of 110.61%.

When did Arcadia Biosciences' stock split?

Arcadia Biosciences shares reverse split before market open on Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Arcadia Biosciences IPO?

Arcadia Biosciences (RKDA) raised $66 million in an initial public offering (IPO) on Friday, May 15th 2015. The company issued 8,200,000 shares at $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO.

How do I buy shares of Arcadia Biosciences?

Shares of RKDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Arcadia Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Arcadia Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), PayPal (PYPL), General Electric (GE), Arista Networks (ANET), Advanced Micro Devices (AMD) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 8/13/2024
• Today: 12/30/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Basic Materials
• Industry: Agricultural production - crops
• Sub-Industry: Agriculture
• Current Symbol: NASDAQ:RKDA
• CUSIP: N/A
• CIK: 1469443
• Web: www.arcadiabio.com
• Phone: (530) 756-7077
• Fax: 530-756-7027
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $6.00
• High Stock Price Target: $6.00
• Low Stock Price Target: $6.00
• Potential Upside/Downside: +0.3%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($4.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-13,980,000.00
• Net Margins: -110.61%
• Pretax Margin: -156.15%
• Return on Equity: -52.63%
• Return on Assets: -34.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.60
• Quick Ratio: 4.24

Sales & Book Value

• Annual Sales: $5.48 million
• Price / Sales: 1.49
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.44 per share
• Price / Book: 0.52

Miscellaneous

• Outstanding Shares: 1,365,000
• Free Float: 1,340,000
• Market Cap: $8.16 million
• Optionable: Not Optionable
• Beta: 1.18